Home


Reducing diabetic distress by controlling oxidative stress 

The primary goal of Glucox Biotech AB, a Swedish research company based in Stockholm, is to develop clinically applicable therapeutics for treatment of type 2 diabetes and diabetic complications. 

The idea behind Glucox Biotech’s diabetes therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species and thus improve blood glycemic control and also decrease the critical risks and delay progression of complications in type 2 patients. 

Glucox Biotech owns several patents covering the exclusive rights to develop pharmaceutical substances for treating insulin resistance and diabetes on the basis of reducing reactive oxygen species produces by NAD(P)H-oxidase (NOX4). 

---------------------------------------------------------------------------------------------------------------------------------------------
February 9, 2012
X. Wu and coworkers show importance of NOX4 in insulin resistance
"NOX4 pathway as a source of selectivite insulin resistance and responsiveness"
Ref: Wu, X., et al (2012) Arterioscler Thromb Vasc Biol. 2012 Feb 9. (Epubl ahead of print)

--------------------------------------------------------------------------------------------------------------------------------------------
November 20, 2011
New publication from Glucox Biotech and academic partners
"Shikonin increases glucose uptake in skeletal muscle cells and improves plasma glucose levels in diabetic Goto-Kakizaki rats".
Ref: Öberg, A.I., et al (2011) PLoS One, 6 (7): e22510

--------------------------------------------------------------------------------------------------------------------------------------------
October 03, 2011
Agreement with Redoxis AB
Glucox Biotech has signed an agreement with Redoxis AB for further development of Glucox´ lead compound for treatment of type 2 diabetes and complications.

---------------------------------------------------------------------------------------------------------------------------------------------
March 14, 2011
Agreement with Department of Pharmacy, Uppsala University
Glucox Biotech annnounces the signing of an agreement with Department of Pharmacy, Uppsala University for the further characterization of Glucox' small molecule inhibitors of NOX4.

---------------------------------------------------------------------------------------------------------------------------------------------
December 22, 2010
Agreement with Redoxis AB
Glucox Biotech announces the signing of a contract with Redoxis AB for further studie on Glucox smal molecule NOX4 inhibitors.

---------------------------------------------------------------------------------------------------------------------------------------------
August 29, 2010
Change of CEO
Erik Walum has been appointed new CEO of Glucox Biotech. Mona Wilcke is the new Chair of Board of Directors

---------------------------------------------------------------------------------------------------------------------------------------------
April 29, 2010 
Approval of patent in Europe 
Glucox Biotech has been approved its third patent application in Europe in April 2010. 

Read more 
---------------------------------------------------------------------------------------------------------------------------------------------
April 15, 2010 
Initiation of animal studie case for novel compounds 
Glucox Biotech has initiated a comprehensive animal study. 

Read more